| AZN Stock | | | SEK 1,471 1.00 0.07% |
Director
Mr. Marc Dunoyer is an Executive Director, Chief Financial Officer of AstraZeneca PLC. His career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline, has given him extensive industry experience, including finance and accounting corporate strategy and planning research and development sales and marketing business reorganisation and business development. Marc qualified as an accountant and joined AstraZeneca in 2013, serving as Executive VicePresident, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University. since 2013.
| Age | 71 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset
(ROA) of
0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96
B in total debt with debt to equity ratio
(D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC operates under Drug ManufacturersGeneral classification in Sweden and is traded on Stockholm Stock Exchange. It employs 83100 people. AstraZeneca PLC (AZN) is traded on Stockholm Exchange in Sweden and employs 37 people.
Management Performance
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | |
| Chris Sheldon, Head Relations | |
| Pam Cheng, Executive Vice-President of Operations and Information Technology | |
| MBA DVM, CEO Director | |
| Gonzalo Vina, Head Relations | |
| Aradhana MD, CFO Director | |
| Menelas Pangalos, Executive Vice President - Innovative Medicines | |
| Katarina Ageborg, Chief Compliance Officer | |
| Jeffrey Pott, General Counsel | |
| Ruud Dobber, Executive Vice President Europe | |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to
measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to
predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.